Understanding the Tip:
Why physical stability is critical for suspensions:
Pharmaceutical suspensions contain dispersed solid particles in a liquid medium. Over time, particles may undergo physical changes such as crystal growth or irreversible aggregation. These changes reduce redispersibility, affect sedimentation behavior, and lead to non-uniform dosing. During stability studies, visual inspection alone is insufficient to detect such transformations. Monitoring crystal size and aggregation behavior is essential to maintaining product efficacy and regulatory compliance.
Consequences of undetected physical changes in suspensions:
Crystal growth or aggregation can lead to:
- Settling and caking, making the product hard to shake and re-suspend
- Variation in dose with each use
- Increased risk of dosing errors or sub-therapeutic effects
- Regulatory concerns over stability, performance, and patient safety
Neglecting to monitor these changes compromises both product performance and compliance with global expectations for suspension dosage forms.
Regulatory and Technical Context:
ICH and WHO expectations for suspension stability:
ICH Q1A(R2) and WHO TRS 1010 mandate monitoring of both chemical and physical parameters during stability studies. For suspensions, this includes sedimentation behavior, redispersibility, and appearance. Regulatory authorities expect that companies evaluate and document any physical instability that might compromise dose uniformity, particularly for pediatric, oral, or ophthalmic suspensions. CTD Module 3.2.P.8.3 must include references to physical stability data.
Audit readiness and quality risk
Regulators and auditors often assess whether physical characteristics like viscosity, particle size, and sediment volume are tracked across stability time points. Failure to evaluate these parameters may trigger audit observations or necessitate product recalls. Proper control of aggregation and crystal growth is especially important for products with narrow therapeutic windows or variable patient compliance.
Best Practices and Implementation:
Use quantitative and qualitative methods to monitor physical stability:
Incorporate the following into your stability protocol:
- Microscopic analysis to detect changes in crystal morphology
- Laser diffraction or dynamic light scattering for particle size distribution
- Visual inspection and sedimentation volume ratio (SVR)
- Redispersibility testing—standardized inversion or mechanical shaking protocols
Evaluate data at key intervals (e.g., 0M, 3M, 6M, 12M) under ICH long-term and accelerated conditions.
Establish clear acceptance criteria and reference data:
Define limits for:
- Maximum allowable particle growth (e.g., < 10% increase in D90)
- Acceptable redispersion time (e.g., < 30 seconds with 10 inversions)
- Visual appearance (no caking, no excessive sediment layer)
Compare results against freshly prepared samples to ensure consistency and stability over time.
Investigate and document any observed changes:
Any increase in particle size or aggregation during stability should trigger:
- Root cause analysis to determine mechanism (e.g., Ostwald ripening, pH drift)
- Review of excipient composition or manufacturing process
- Risk assessment for shelf-life and regulatory filing impact
Document findings in your stability summary and reflect conclusions in the final CTD submission.
Evaluating crystal growth and aggregation in suspensions isn’t optional—it’s critical for ensuring dose uniformity, therapeutic effectiveness, and regulatory trust throughout the product lifecycle.